Advanced search
Publication Cover
OncoImmunology Volume 3, 2014 - Issue 2
Submit an article Journal homepage
250
Views
17
CrossRef citations to date
0
Altmetric
Author's View

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses

Shashi Gujar Department of Microbiology and Immunology; Dalhousie University; Halifax, NS Canada; Strategy & Organizational Performance; IWK Health Centre; Halifax, NS Canada
,
Derek Clements Department of Pathology; Dalhousie University; Halifax, NS Canada
&
Patrick W.K. Lee Department of Microbiology and Immunology; Dalhousie University; Halifax, NS Canada; Department of Pathology; Dalhousie University; Halifax, NS CanadaCorrespondence[email protected]
Article: e27622 | Received 21 Dec 2013, Accepted 22 Dec 2013, Published online: 06 Jan 2014
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Abstract

Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its immunostimulatory effects, hence exerting superior antineoplastic activity.

Related Research Data

First oncolytic virus approved for melanoma immunotherapy.
Source: Informa UK Limited
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
Source: Informa UK Limited
Trial watch: IDO inhibitors in cancer therapy
Source: Informa UK Limited

Linking provided by 
Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.